BioCentury
ARTICLE | Clinical News

Adcirca regulatory update

February 18, 2013 8:00 AM UTC

Last month, the U.K.'s NICE said it terminated an appraisal for Cialis tadalafil to treat signs and symptoms of benign prostatic hyperplasia (BPH) because it did not receive an evidence submission from Eli Lilly. Last year, the European Commission approved a label expansion for 5 mg Cialis to include the treatment of signs and symptoms of BPH in adult males, including those with erectile dysfunction (ED) (see BioCentury, Nov. 5, 2012). ...